pilaralisib   Click here for help

GtoPdb Ligand ID: 7963

Synonyms: SAR-245408 | XL-147 | XL147
Compound class: Synthetic organic
Comment: Pilaralisib is an orally bioavailable small molecule inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential antineoplastic activity [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 146.38
Molecular weight 448.08
XLogP 4.95
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2c(c1)nsn2
Isomeric SMILES Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2c(c1)nsn2
InChI InChI=1S/C21H16N6O2S2/c1-13-6-9-15(10-7-13)31(28,29)27-21-20(23-16-4-2-3-5-17(16)24-21)22-14-8-11-18-19(12-14)26-30-25-18/h2-12H,1H3,(H,22,23)(H,24,27)
No information available.
Summary of Clinical Use Click here for help
Pilaralisib has previously been reported using the research codes XL147 and SAR245408 and both of these codes are used in the ClinicalTrials.gov registry. Phase 1 clinical trial results have been published [2]. Phase 1/2 trials for breast and endometrial cancers have been completed, as has an extension study (NCT01587040) in patients who have previously received SAR245408 treatment.